Online citations, reference lists, and bibliographies.

Tumour Growth Fraction Measured By Immunohistochemical Staining Of Ki67 Is An Independent Prognostic Factor In Preoperative Prostate Biopsies With Small‐volume Or Low‐grade Prostate Cancer

T. Zellweger, S. Günther, I. Zlobec, S. Savic, G. Sauter, H. Moch, G. Mattarelli, Tobias Eichenberger, E. Curschellas, H. Rüfenacht, A. Bachmann, T. Gasser, M. Mihatsch, L. Bubendorf
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Accurate prognostic parameters in prostate biopsies are needed to better counsel individual patients with prostate cancer. We evaluated the prognostic impact of morphologic and immunohistochemical parameters in preoperative prostate cancer biopsies. A consecutive series of prostate biopsies of 279 men (72% with clinical stage T1c and 23% with T2) who subsequently underwent radical prostatectomy was prospectively analysed for Gleason score, number and percentage of positive cores (NPC, PPC), total percentage of biopsy tissue with tumour (TPT), maximum tumour percentage per core (MTP), and expression of Ki67, Bcl‐2 and p53. All biopsy features were significantly associated with at least one feature of the radical prostatectomy specimen. pT stage was independently predicted by PSA, seminal vesicle invasion by Ki67 LI, positive margins by PSA and MTP, large tumour diameter by PSA and PPC, and Gleason score by biopsy Gleason score, MTP, and Ki67 LI, respectively. Biopsy Gleason score, NPC (1 vs. >1), TPT (<7 vs. ≥7%), and Ki67 LI (<10 vs. ≥10%) were significant predictors of biochemical recurrence after radical prostatectomy (p < 0.01, each). KI67 LI was the only independent prognostic factor in case of a low TPT (<7%) or low Gleason score (<7), the hazard ratio being 6.76 and 6.44, respectively. In summary, preoperative Gleason score, NPC, TPT and Ki67 LI significantly predict the risk of recurrence after radical prostatectomy, and Ki67 is an independent prognosticator in biopsies with low‐volume or low‐grade prostate cancer. Analysis of Ki67 LI in these biopsies may help to better identify patients with clinically insignificant prostate cancer. © 2008 Wiley‐Liss, Inc.
This paper references
10.1136/jcp.56.5.336
Guidelines for processing and reporting of prostatic needle biopsies
T. van der Kwast (2003)
10.1016/J.EURURO.2006.07.042
Prostate cancer nomograms: an update.
F. Chun (2006)
Factores pronósticos del cáncer de próstata: utilidad de la expresión del Ki67 en las biopsias preoperatorias
J. Rodríguez (2004)
10.1016/J.EURURO.2005.06.014
Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
J. Rubio (2005)
10.1002/cncr.11230
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma
A. Pollack (2003)
10.1016/J.HUMPATH.2005.10.011
Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists.
L. Egevad (2006)
10.1002/PROS.10209
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
T. Zellweger (2003)
10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy.
L. Bubendorf (1996)
10.1002/cncr.23107
Predicting survival for men with clinically localized prostate cancer
P. Albertsen (2008)
on biopsy : what are the risks of progression ? . A systematic review and meta - analysis
S Jhavar (2008)
10.1093/JNCI/DJJ190
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
A. Stephenson (2006)
10.1200/JCO.2004.09.150
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
A. Pollack (2004)
10.1002/ijc.20615
Expression patterns of potential therapeutic targets in prostate cancer
T. Zellweger (2005)
[Active surveillance for early-stage prostate cancer].
P. Jichlinski (2009)
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
D. Cowen (2002)
10.1093/AJCP/110.4.443
Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma.
A. Keshgegian (1998)
10.1056/NEJMCP0706784
Localized Prostate Cancer
P. Walsh (2007)
10.1016/J.IJROBP.2007.08.021
Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance.
S. Williams (2008)
10.1016/J.EURURO.2007.01.015
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
M. Simmons (2007)
International Union Against Cancer: Classification of malignant tumors, 6 edn
(2002)
10.1016/J.JURO.2006.08.014
Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
N. Fitzsimons (2006)
10.1038/pcan.2008.47
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance
S. Jhavar (2009)
10.1016/J.EURURO.2007.02.054
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
A. Briganti (2007)
10.1002/PATH.1084
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
A. Vis (2002)
10.1007/s00345-008-0277-9
What is low-risk prostate cancer and what is its natural history?
H. O’Donnell (2008)
10.1016/S0022-5347(01)65703-3
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
M. C. Bettencourt (1996)
10.1043/1543-2165(2006)130[936:UPFTEO]2.0.CO;2
Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland.
J. Srigley (2006)
Maximum Ki67 staining in prostate cancer provides independent prognostic information after radical prostatectomy
OJ Halvorsen (2001)
10.1016/S0022-5347(05)00056-X
Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE.
K. Greene (2006)
10.1016/j.urology.2007.10.022
Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years.
A. Rajinikanth (2008)
: what do we need in contemporary practice
H O’Donnell (2008)
Cancer Stat , 2008
PC Walsh
10.1038/sj.bjc.6603718
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
T. Dudderidge (2007)
10.1097/00000478-200204000-00004
Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer
T. Sebo (2002)
10.1093/JNCI/95.9.661
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
D. Rhodes (2003)
10.1007/s00345-008-0257-0
Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability
S. Gunia (2008)
Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy.
O. J. Halvorsen (2001)
10.3322/CA.2007.0010
Cancer Statistics, 2008
A. Jemal (2008)
10.1016/S0090-4295(99)00166-1
Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy.
X. Yang (1999)
10.1016/J.EJCA.2004.12.035
Molecular markers of prostate cancer outcome.
D. Quinn (2005)
10.1001/JAMA.281.17.1591
Natural history of progression after PSA elevation following radical prostatectomy.
C. Pound (1999)
10.1002/(SICI)1097-0045(19991101)41:3<166::AID-PROS3>3.0.CO;2-E
Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
V. Khoo (1999)
10.1002/cncr.23277
The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?
P. Harnden (2008)
10.1002/ijc.23145
EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients
Sari Laitinen (2008)
10.1007/BF00372800
Review of current literature
(1993)
Clinical practice. Localized prostate cancer.
P. Walsh (2007)
[Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies].
A. Ojea Calvo (2004)
10.1158/1078-0432.CCR-06-0147
Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy
Tateki Yoshino (2006)
10.1016/J.EURURO.2005.06.016
Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy.
F. Algaba (2005)
10.1158/1078-0432.CCR-04-2145
A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
A. Tolcher (2005)
10.1016/S0022-5347(05)66989-3
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
A. Vis (2000)
10.1016/S0046-8177(98)90199-X
Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
L. Bubendorf (1998)
cancer treated with radiotherapy
TJ Dudderidge (1999)
10.1002/cncr.11153
Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma
A. Haese* (2003)
10.1046/j.1464-410X.2002.02541.x
p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy
J. Oxley (2002)
10.1158/1078-0432.CCR-06-2972
Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02
L. Y. Khor (2007)
10.1200/JCO.2005.08.904
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
A. D'Amico (2005)
Prognostic significance of Bcl-2 in clinically localized prostate cancer.
L. Bubendorf (1996)
10.1016/S0022-5347(01)69076-1
Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
S. Freedland (2002)



This paper is referenced by
10.5858/arpa.2020-0015-RA
The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
Jonathan I Epstein (2020)
10.1007/s13277-015-4398-7
Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer
Shibao Li (2015)
10.1007/s00292-015-0123-y
[Prostate cancer. Part 1: Review of cell kinetics over the years 1966-2015 and future perspectives of the new grading of the International Society of Urological Pathology (ISUP)].
Bernd Helpap (2016)
10.5114/PJP.2012.32480
Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer.
E. Luczynska (2012)
10.1186/s13000-015-0294-0
Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy
P. Desmeules (2015)
10.1158/1078-0432.CCR-15-0635
The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Maximilian Lennartz (2016)
Role of ERG, PTEN and KI67 Proteins Expression in Prognosis of Metastatic Prostate Cancer
Eman Hassan Abdelbary (2015)
10.3389/fonc.2018.00377
The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature
A. Carneiro (2018)
10.1371/journal.pone.0020293
A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer
S. Malhotra (2011)
10.3390/ijms140612620
The Present and Future of Prostate Cancer Urine Biomarkers
M. Rigau (2013)
10.1002/ijc.24842
Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?
Claude A. Fischer (2010)
10.1016/j.molonc.2013.07.009
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
K. Grupp (2013)
10.1371/journal.pone.0186852
Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort
E. Richardsen (2017)
10.1158/0008-5472.CAN-09-4100
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
M. Fiorentino (2010)
10.3892/ijo.2011.1216
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers.
P. Tennstedt (2012)
10.1007/s00345-014-1421-3
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy
R. Mathieu (2014)
10.1097/PAT.0000000000000320
Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer
D. Goltz (2015)
10.3892/ijo.2013.2173
Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research.
A. Komiya (2014)
Discovery and validation of prognostic tissue markers in clinical prostate cancer
M. Hoogland (2015)
10.2478/v10140-009-0006-8
Relationship between growth fraction and clonogenic survival after ionizing irradiation in pancreatic MiaPaCa2 cells
D. Characiejus (2009)
10.1016/j.exphem.2010.03.022
Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
M. Mossner (2010)
10.2217/fon.10.4
Effect of the number of biopsy cores on prostate cancer detection and staging.
G. Lughezzani (2010)
10.1371/journal.pone.0021366
MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
L. von Boehmer (2011)
10.1007/978-3-319-42769-0_19
Salvage Prostate Brachytherapy for Postradiation Local Failure
Gilles Créhange (2017)
10.1109/ICSP.2016.7877789
Cancer lesion screening in MRI for prostate biopsy
Yun-jie Chen (2016)
10.1007/s10552-019-1128-2
Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients
Adrian Rosenberg (2019)
10.1684/BDC.2010.1228
Cancers de la prostate cliniquement localisés à haut risque de progression
François Rozet (2010)
10.1371/journal.pone.0041664
Role of KCNMA1 in Breast Cancer
M. Oeggerli (2012)
10.1002/cmmi.1675
Magnetite loaded Polypeptide-PLGA multifunctional microbubbles for dual-mode US/MR imaging.
Ying Sun (2016)
10.1111/j.1464-410X.2011.10253.x
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki‐67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine‐treated prostate cancer
T. Tolonen (2011)
10.26508/lsa.201800042
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers
Tiannan Guo (2018)
Analyse d'une série de 1880 biopsies prostatiques réalisées au Centre Hospitalier Universitaire de Martinique de mars 2013 à mai 2016
J. Tantot (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar